Aardvark Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2023 | — | $-34.8M | $9.7M |
| FY2024 | — | $-54.6M | $61.6M |
| FY2025 | — | $106.6M | $47.1M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2023 | — | $-34.8M | $9.7M |
| FY2024 | — | $-54.6M | $61.6M |
| FY2025 | — | $106.6M | $47.1M |